Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Glucophage IR (China vs France) in Healthy Subjects
NCT03393208Phase 1Completed
- Sponsor
- Merck KGaA
- Start
- Jan 2018
- Primary completion
- Jan 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of metformin in type 2 diabetes mellitus (T2DM) (4 arms), sponsored by Merck KGaA. Primary endpoints: Area Under the Plasma Concentration-Time Curve From Time Zero to the Last Sampling Time at Day 3 and Maximum Observed Plasma Concentration at Day 3. Started Jan 2018; status: completed.
02
Drugs
metformin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT03393208.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03393208.